Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Ironwood Pharmaceuticals Lowers 2024 Guidance: Now Expects Sales Between $405M-$425M (Prior $435M-$455M) Vs. 447.9M Consensus; Sees Adjusted EBITDA Above $120M

Author: Benzinga Newsdesk | May 09, 2024 07:31am
  • Ironwood 2024 Financial Guidance. Ironwood has revised its FY 2024 financial guidance due to a LINZESS gross-to-net change in estimate related to the year ended December 31, 2023. Ironwood now expects:

 

Prior 2024 Guidance

(February 15, 2024)

Revised 2024 Guidance2

(May 9, 2024)

U.S. LINZESS Net Sales3

Low-single digits % growth

Mid-single digits % decline

Total Revenue

$435 to $455 million

$405 to $425 million

Adjusted EBITDA1

>$150 million

Excludes potential CNP-104 option exercise

>$120 million

Excludes potential CNP-104 option exercise

Posted In: IRWD


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist